Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ankyrin repeat and LEM domain-containing protein 1 (ANKLE1) is a mammalian endonuclease characterized by a C-terminal GIY-YIG motif and an internal LEM domain. It cleaves branched DNA species, such as four-way junctions and Y-structures, and shuttles between the nucleus and cytoplasm. In normal physiology, ANKLE1 is primarily expressed in erythroblast lineage cells, where it facilitates mitochondrial genome degradation during erythropoiesis. Ectopic or high expression in non-hematopoietic cells leads to mitochondrial and genome instability, triggers DNA damage responses, and is associated with increased risk for cancer (notably breast and ovarian). Mechanistically, ANKLE1’s activity can induce mitophagy, metabolic reprogramming to increased glycolysis, and may confer resistance to apoptosis. While essential for mitochondrial clearance in maturing red blood cells, its broader physiological and pathological roles outside the erythroid lineage remain incompletely defined[1][2][3][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ankyrin repeat and LEM domain-containing protein 1 (ANKLE1).